Search

Transactions of the Leicestershire Archaeological and Historical Society, 84, 213-222, This paper presents the evidence for a number of sunken-featured buildings dating to the Romano-British period, excavated in 1999 by the University of Leicester Archaeological Services. These buildings formed part of a small, fourth-century agricultural settlement, located at a site close to the village of Appleby Magna. Structures of this type are more commonly associated with Anglo-Saxon settlement from the fifth century onwards, but there is increasing evidence to indicate an earlier origin for this building tradition. more...

Transactions of the Leicestershire Archaeological and Historical Society, 80, 61-70, This paper is based upon an RCHME level 3 survey of Oram Cottage, Church Lane, Knighton, Leicester (SK 5998 0130), undertaken in 2003 as part of coursework requirements for a Masters degree in Archaeology and Heritage at Leicester University. Oram Cottage is one of the few surviving examples of timber-framed building in Leicester and survey has revealed several phases of internal modification, resulting in the replacement of much of the early building fabric. Restoration of the property, undertaken by Leicester City Council in 1961, apparently sought to replicate a symmetrical aspect to the façade, for which there is no peg-hole evidence. Despite the later modifications, an original three-bay structure of one and a half storeys, with cross-passage entrance can be inferred from evidence in the early surviving timber work. more...

BACKGROUND: Glucagon-like peptide-1 (7-36) amide (GLP-1) protects against stunning and cumulative left ventricular dysfunction in humans. The mechanism remains uncertain but GLP-1 may act by opening mitochondrial K-ATP channels in a similar fashion to ischemic conditioning. We investigated whether blockade of K-ATP channels with glibenclamide abrogated the protective effect of GLP-1 in humans. METHODS: Thirty-two non-diabetic patients awaiting stenting of the left anterior descending artery (LAD) were allocated into 4 groups (control, glibenclamide, GLP-1, and GLP-1 + glibenclamide). Glibenclamide was given orally prior to the procedure. A left ventricular conductance catheter recorded pressure-volume loops during a 1-min low-pressure balloon occlusion (BO1) of the LAD. GLP-1 or saline was then infused for 30-min followed by a further 1-min balloon occlusion (BO2). In a non-invasive study, 10 non-diabetic patients were randomized to receive two dobutamine stress echocardiograms (DSE) during GLP-1 infusion with or without oral glibenclamide pretreatment. RESULTS: GLP-1 prevented stunning even with glibenclamide pretreatment; the Δ % dP/dtmax 30-min post-BO1 normalized to baseline after GLP-1: 0.3 ± 6.8 % (p = 0.02) and GLP-1 + glibenclamide: -0.8 ± 9.0 % (p = 0.04) compared to control: -11.5 ± 10.0 %. GLP-1 also reduced cumulative stunning after BO2: -12.8 ± 10.5 % (p = 0.02) as did GLP-1 + glibenclamide: -14.9 ± 9.2 % (p = 0.02) compared to control: -25.7 ± 9.6 %. Glibenclamide alone was no different to control. Glibenclamide pretreatment did not affect global or regional systolic function after GLP-1 at peak DSE stress (EF 74.6 ± 6.4 vs. 74.0 ± 8.0, p = 0.76) or recovery (EF 61.9 ± 5.7 vs. 61.4 ± 5.6, p = 0.74). CONCLUSIONS: Glibenclamide pretreatment does not abrogate the protective effect of GLP-1 in human models of non-lethal myocardial ischemia. Trial registration Clinicaltrials.gov Unique Identifier: NCT02128022. more...